EPM Is working to develop innovative drugs inspired by the cannabis plant, in order to treat two main diseases of Frader-Willi syndrome and skin infections – psoriasis. To meet the task, and try to improve the quality of life of those suffering from these diseases, succeeded EPM enlists the help of leading research institutes and universities in Israel and around the world and a number of key figures from the Israeli and international pharmaceutical industry, who have been appointed to management positions at EPM, on their way to an IPO on the Tel Aviv Stock Exchange.
EPM Was able to artificially and stably mimic the activity of cannabinoids, which serve as a source of known active ingredients, THC and CBD, in the cannabis plant. All this is done with the aim of expanding the medicinal potential of the plant for conventional treatment, using prescription drugs. EPM’s research, in conjunction with the Hebrew University of Jerusalem, has led to the development and production of 14 innovative molecules from the plant, for which patent applications have been filed and are in various approval stages. EPM You will begin in the coming year clinical trials with the aim of developing drugs, from those molecules, which are designed to improve the quality of life of those suffering from the diseases that the drugs will treat.
shutterstock | Monkey Business Images
Minimum side effects
The development of the EPM company May bring a line to many patients around the world, who do not have an optimal solution in hand today. In the current situation, many patients are forced to use medications to relieve inflammation and relieve pain, which cause side effects that can impair patients’ quality of life and even be difficult to use over time.
This problem is exactly EPM Trying to solve. Based on existing knowledge, the cannabis plant possesses extensive medicinal properties with a minimum of side effects, but its effectiveness is limited.
In its activity EPM strives to translate the promising substances synthetically, preserving the minimal side effects while increasing the effectiveness of the substances and creating a prescription drug in accordance with regulatory requirements from the US FDA. The goal is for patients with diseases, which are chronic diseases that accompany patients throughout their lives, to have another option in an effort to lead to improvement in the health of many people.
The company’s headquarters and development center are in Israel, with another office in Los Angeles. EPM, led by entrepreneur Reshef Suissa, works with key figures from the international pharmaceutical industry, such as Julian Gangoli, chairman of the board of directors, who served as president of the large pharmaceutical company GW (which was recently sold for about $ 7 billion) and the Israeli healthcare industry. The company, Prof. Zeev Rothstein. In addition, the company works in collaboration with leading researchers from the major universities in Israel, such as: Prof. Rafael Meshulam, Prof. Dan Peer, Prof. Yossi Tam, Prof. Dror Robinson. For several years, the company’s activities have also involved hospitals and three universities in Israel, including the Hebrew University, Tel Aviv University and Bar Ilan University, in addition to Guelph and McMaster Universities in Canada.
Uniquely in the local capital market landscape, the company goes public on the Israeli stock exchange before entering the clinical trials phase in humans. Therefore, it is an investment in a company that is at the beginning of its path and the fruits, if any, will be reaped along the way.